SCHEMBL3540880

SCHEMBL3540880

CC(C)(C)N(Cc1ccc(N)c2ccccc12)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 4/20 0.38
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MAPT P10636 2/20 0.37
TP53 P04637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CHEK1 O14757 1/20 0.37
NEK2 P51955 1/20 0.37
LIMK1 P53667 1/20 0.37
DYRK1A Q13627 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
HDAC3 O15379 1/20 0.36
IDO1 P14902 1/20 0.36
EP300 Q09472 1/20 0.36
KAT2B Q92831 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2340705 0.81 MEN1 (0.46) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL21751181 0.80 CHEK1 (0.43) MEN1KMT2AL3MBTL1LMNAALDH1A1
SCHEMBL862315 0.78 MEN1 (0.42) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL1799391 0.75 MEN1 (0.46) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL8773482 0.73 MEN1 (0.69) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL3461483 0.73 AKR1B1 (0.48) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL5514821 0.72 KMT2A (0.48) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL28469180 0.71 IDO1 (0.54) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL13912445 0.71 TDP1 (0.56) ALDH1A1HDAC3IDO1EP300KAT2B
SCHEMBL14674364 0.71 LPAR1 (0.46) MEN1KMT2AHTTL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741479-B2 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. (US) 2010-06-22 US disclosed
EP-1828169-A2 UREA INHIBITORS OF MAP KINASES Locus Pharmaceuticals, Inc. (US) 2007-09-05 EP disclosed
US-20060167247-A1 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. 2006-07-27 US disclosed
WO-2006062982-A2 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167247-A1 Urea inhibitors of MAP kinases MAPK1, MAP3K1, MAP3K20 MEN1 4186/4885KMT2A 2250/4885HTT 3278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.